Healthcare professionals across multiple specialties are advocating for a significant shift in how polycystic ovary syndrome is named and understood. The proposed terminology change to ‘metabolic reproductive syndrome’ aims to address a fundamental gap between the condition’s current name and its clinical reality. Medical experts highlight that only 20% of diagnosed patients actually present with ovarian cysts, while the majority experience significant metabolic dysfunction including insulin resistance affecting 70% of cases. Dr. Sarah Mitchell, endocrinologist at Jersey General Hospital, notes that the misleading nomenclature contributes to delayed diagnosis and inadequate treatment of non-reproductive manifestations. The syndrome affects 10-15% of reproductive-age women worldwide, with metabolic components proving more clinically consequential than ovarian symptoms for long-term health outcomes. International medical organizations are reviewing this nomenclature change as part of broader efforts to align diagnostic terminology with disease mechanisms rather than historical conventions.
Was this article helpful?
